Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: Genetic analysis prior to transplantation is essential

Clinical Kidney Journal

Volumn 10, Issue 4, 2017, Pages 490-493

  Dowen, Frances ^a   Wood, Katrina ^b   Brown, Alison L ^c   Palfrey, Jennifer ^a   Kavanagh, David ^b   Brocklebank, Vicky ^b  

^a SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

Author keywords

atypical haemolytic uraemic syndrome; complement; eculizumab; renal transplantation; STEC HUS

Indexed keywords

AMINO ACID; BASILIXIMAB; BILIRUBIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; ECULIZUMAB; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; HEMOGLOBIN; IMMUNOGLOBULIN M ANTIBODY; INOTROPIC AGENT; ISOTRETINOIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; SHIGA TOXIN; TACROLIMUS;

ACNE; ACUTE DISEASE; ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADOLESCENT; ARTICLE; ASSISTED VENTILATION; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE REGULATION; BLURRED VISION; BRAIN DEAD DONOR; CASE REPORT; CEREBRAL BLINDNESS; CLINICAL ARTICLE; COMPLEMENT DEPOSITION; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; DETERIORATION; DISEASE EXACERBATION; DISEASE SEVERITY; ERYTHROCYTE COUNT; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157:H7; FEMALE; GENETIC ANALYSIS; GENETIC COMPLEMENTATION; GENETIC VARIABILITY; HEADACHE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; HETEROZYGOTE; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; IMMUNOFLUORESCENCE; INOTROPISM; INTENSIVE CARE UNIT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAINTENANCE THERAPY; MEDICAL HISTORY; MICROANGIOPATHIC HEMOLYTIC ANEMIA; MISMATCHED UNRELATED DONOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOPHOBIA; PLASMA EXCHANGE; PLATELET COUNT; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; RETICULOCYTE COUNT; SEROLOGY; TONIC CLONIC SEIZURE; TREATMENT RESPONSE; VOMITING;

EID: 85037985917     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfx030     Document Type: Article

References (28)

1. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013; 33: 508-530
2. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365: 1073-1086
3. Lynn RM, O'Brien SJ, Taylor CM et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 2005; 11: 590-596
4. Siegler R, Oakes R. Hemolytic uremic syndrome; pathogenesis, treatment, and outcome. Curr Opin Pediatr 2005; 17: 200-204
5. Sheerin NS, Kavanagh D, Goodship TH et al. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 2016; 109: 27-33
6. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1159
7. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8: 554-562
8. Bassani CE, Ferraris J, Gianantonio CA et al. Renal transplantation in patients with classical haemolytic-uraemic syndrome. Pediatr Nephrol 1991; 5: 607-611
9. Ferraris JR, Ramirez JA, Ruiz S et al. Shiga toxin-associated hemolytic uremic syndrome: Absence of recurrence after renal transplantation. Pediatr Nephrol 2002; 17: 809-814
10. Chart H, Cheasty T. Human infections with verocytotoxinproducing Escherichia coli O157-10 years of E. coli O157 serodiagnosis. J Med Microbiol 2008; 57: 1389-1393
11. Zuber J, Le Quintrec M, Krid S et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 12: 3337-3354
12. Sartz L, Olin AI, Kristoffersson AC et al. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol 2012; 188: 2030-2037
13. Wu J, Wu YQ, Ricklin D et al. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol 2009; 10: 728-733
14. Forneris F, Ricklin D, Wu J et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 2010; 330: 1816-1820
15. Banatvala N, Griffin PM, Greene KD et al. The United States National Prospective Hemolytic Uremic Syndrome Study: Microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001; 183: 1063-1070
16. Brandt JR, Fouser LS, Watkins SL et al. Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 1994; 125: 519-526
17. Bryan A, Youngster I, McAdam AJ. Shiga toxin producing Escherichia coli. Clin Lab Med 2015; 35: 247-272
18. Jenkins C, Lawson AJ, Cheasty T et al. Assessment of a realtime PCR for the detection and characterization of verocytotoxigenic Escherichia coli. J Med Microbiol 2012; 61: 1082-1085
19. Le Quintrec M, Zuber J, Moulin B et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013; 13: 663-675
20. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10: 1517-1523
21. Goodship TH, Cook HT, Fakhouri F et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: Conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017; 91: 539-551
22. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18: 2392-2400
23. Caillaud C., Zaloszyc A, Licht C et al. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 2016; 31: 157-161
24. Ahlenstiel-Grunow T, Hachmeister S, Bange FC et al. Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome. Nephrol Dial Transplant 2016; 31: 1114-1121
25. Challis RC, Araujo GS, Wong EK et al. A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2016; 27: 1617-1124
26. Alberti M, Valoti E, Piras R et al. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. Am J Transplant 2013; 13: 2201-2206
27. Herlitz LC, Bomback AS, Markowitz GS et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23: 1229-1237
28. Wong E, Challis R, Sheerin N et al. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology 2016; 221: 715-718